CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Chromosomal Abnormalities
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Aneuploidy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 X-linked diseases
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Single Gene Disorders
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 HLA Typing
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Gender selection
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
4.8 Others
4.8.1 Key market trends, growth factors and opportunities
4.8.2 Market size and forecast, by region
4.8.3 Market analysis by country
CHAPTER 5: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 Asia-Pacific
5.2.1 Key trends and opportunities
5.2.2 Asia-Pacific Market size and forecast, by Test Type
5.2.3 Asia-Pacific Market size and forecast, by country
5.2.3.1 China
5.2.3.1.1 Market size and forecast, by Test Type
5.2.3.2 Japan
5.2.3.2.1 Market size and forecast, by Test Type
5.2.3.3 India
5.2.3.3.1 Market size and forecast, by Test Type
5.2.3.4 South Korea
5.2.3.4.1 Market size and forecast, by Test Type
5.2.3.5 Rest Of Asia Pacific
5.2.3.5.1 Market size and forecast, by Test Type
5.3 LAMEA
5.3.1 Key trends and opportunities
5.3.2 LAMEA Market size and forecast, by Test Type
5.3.3 LAMEA Market size and forecast, by country
5.3.3.1 Latin America
5.3.3.1.1 Market size and forecast, by Test Type
5.3.3.2 Middle East
5.3.3.2.1 Market size and forecast, by Test Type
5.3.3.3 Africa
5.3.3.3.1 Market size and forecast, by Test Type
5.4 North America
5.4.1 Key trends and opportunities
5.4.2 North America Market size and forecast, by Test Type
5.4.3 North America Market size and forecast, by country
5.4.3.1 U.S.
5.4.3.1.1 Market size and forecast, by Test Type
5.4.3.2 Canada
5.4.3.2.1 Market size and forecast, by Test Type
5.4.3.3 Mexico
5.4.3.3.1 Market size and forecast, by Test Type
5.5 Europe
5.5.1 Key trends and opportunities
5.5.2 Europe Market size and forecast, by Test Type
5.5.3 Europe Market size and forecast, by country
5.5.3.1 Germany
5.5.3.1.1 Market size and forecast, by Test Type
5.5.3.2 France
5.5.3.2.1 Market size and forecast, by Test Type
5.5.3.3 U.K.
5.5.3.3.1 Market size and forecast, by Test Type
5.5.3.4 Italy
5.5.3.4.1 Market size and forecast, by Test Type
5.5.3.5 Rest of Europe
5.5.3.5.1 Market size and forecast, by Test Type
CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments
CHAPTER 7: COMPANY PROFILES
7.1 Agilent Technologies, Inc.
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 cegat gmbh
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 Illumina Inc.
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 Invitae Corporation
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 Laboratory Corporation of America Holdings
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 Natera Inc.
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 pacgenomics
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 PerkinElmer, Inc.
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 Quest Diagnostics Inc.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 Reproductive Genetic Innovations (RGI)
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments
TABLE 1. GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 2. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR CHROMOSOMAL ABNORMALITIES, BY REGION , 2020-2030,($THOUSAND)
TABLE 3. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET CHROMOSOMAL ABNORMALITIES BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 4. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR ANEUPLOIDY, BY REGION , 2020-2030,($THOUSAND)
TABLE 5. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET ANEUPLOIDY BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 6. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR X-LINKED DISEASES, BY REGION , 2020-2030,($THOUSAND)
TABLE 7. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET X-LINKED DISEASES BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 8. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR SINGLE GENE DISORDERS, BY REGION , 2020-2030,($THOUSAND)
TABLE 9. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SINGLE GENE DISORDERS BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 10. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR HLA TYPING, BY REGION , 2020-2030,($THOUSAND)
TABLE 11. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET HLA TYPING BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 12. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR GENDER SELECTION, BY REGION , 2020-2030,($THOUSAND)
TABLE 13. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET GENDER SELECTION BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 14. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($THOUSAND)
TABLE 15. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET OTHERS BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 16. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION, 2020-2030,($THOUSAND)
TABLE 17. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 18. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 19. CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 20. JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 21. INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 22. SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 23. REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 24. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 25. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 26. LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 27. MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 28. AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 29. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 30. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 31. U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 32. CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 33. MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 34. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
TABLE 35. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
TABLE 36. GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 37. FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 38. U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 39. ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 40. REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
TABLE 41.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 42.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
TABLE 43.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 44.AGILENT TECHNOLOGIES, INC.: NET SALES,
TABLE 45.AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 46.CEGAT GMBH: COMPANY SNAPSHOT
TABLE 47.CEGAT GMBH: OPERATING SEGMENTS
TABLE 48.CEGAT GMBH: PRODUCT PORTFOLIO
TABLE 49.CEGAT GMBH: NET SALES,
TABLE 50.CEGAT GMBH: KEY STRATERGIES
TABLE 51.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 52.ILLUMINA INC.: OPERATING SEGMENTS
TABLE 53.ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 54.ILLUMINA INC.: NET SALES,
TABLE 55.ILLUMINA INC.: KEY STRATERGIES
TABLE 56.INVITAE CORPORATION: COMPANY SNAPSHOT
TABLE 57.INVITAE CORPORATION: OPERATING SEGMENTS
TABLE 58.INVITAE CORPORATION: PRODUCT PORTFOLIO
TABLE 59.INVITAE CORPORATION: NET SALES,
TABLE 60.INVITAE CORPORATION: KEY STRATERGIES
TABLE 61.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 62.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
TABLE 63.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 64.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES,
TABLE 65.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
TABLE 66.NATERA INC.: COMPANY SNAPSHOT
TABLE 67.NATERA INC.: OPERATING SEGMENTS
TABLE 68.NATERA INC.: PRODUCT PORTFOLIO
TABLE 69.NATERA INC.: NET SALES,
TABLE 70.NATERA INC.: KEY STRATERGIES
TABLE 71.PACGENOMICS: COMPANY SNAPSHOT
TABLE 72.PACGENOMICS: OPERATING SEGMENTS
TABLE 73.PACGENOMICS: PRODUCT PORTFOLIO
TABLE 74.PACGENOMICS: NET SALES,
TABLE 75.PACGENOMICS: KEY STRATERGIES
TABLE 76.PERKINELMER, INC.: COMPANY SNAPSHOT
TABLE 77.PERKINELMER, INC.: OPERATING SEGMENTS
TABLE 78.PERKINELMER, INC.: PRODUCT PORTFOLIO
TABLE 79.PERKINELMER, INC.: NET SALES,
TABLE 80.PERKINELMER, INC.: KEY STRATERGIES
TABLE 81.QUEST DIAGNOSTICS INC.: COMPANY SNAPSHOT
TABLE 82.QUEST DIAGNOSTICS INC.: OPERATING SEGMENTS
TABLE 83.QUEST DIAGNOSTICS INC.: PRODUCT PORTFOLIO
TABLE 84.QUEST DIAGNOSTICS INC.: NET SALES,
TABLE 85.QUEST DIAGNOSTICS INC.: KEY STRATERGIES
TABLE 86.REPRODUCTIVE GENETIC INNOVATIONS (RGI): COMPANY SNAPSHOT
TABLE 87.REPRODUCTIVE GENETIC INNOVATIONS (RGI): OPERATING SEGMENTS
TABLE 88.REPRODUCTIVE GENETIC INNOVATIONS (RGI): PRODUCT PORTFOLIO
TABLE 89.REPRODUCTIVE GENETIC INNOVATIONS (RGI): NET SALES,
TABLE 90.REPRODUCTIVE GENETIC INNOVATIONS (RGI): KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/